These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32472757)

  • 1. PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells.
    Li X; Berahovich R; Zhou H; Liu X; Li F; Xu S; Wei Y; Ouaret D; Bodmer W; Wu L; Golubovskaya V
    Front Biosci (Landmark Ed); 2020 Jun; 25(9):1765-1786. PubMed ID: 32472757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
    Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
    Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and Functional Characterization of PLAP CAR-T Cells against Cervical Cancer Cells.
    Yekehfallah V; Pahlavanneshan S; Sayadmanesh A; Momtahan Z; Ma B; Basiri M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
    Li Y; Gao Q; Liu H; Lin S; Chen H; Ding R; Gu Y; Chao CC; Dong X
    Cancer Invest; 2021 Apr; 39(4):285-296. PubMed ID: 33646061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
    Zhang PF; Huang Y; Liang X; Li D; Jiang L; Yang X; Zhu M; Gou HF; Gong YL; Wei YQ; Li Q; Wang W
    FASEB J; 2020 Aug; 34(8):11185-11199. PubMed ID: 32645243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y; Wang J; Yang X; Yang J; Lu P; Zhao L; Li B; Pan H; Jiang Z; Shen X; Liang Z; Liang Y; Zhu H
    Front Immunol; 2021; 12():628906. PubMed ID: 33777013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
    Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
    Front Immunol; 2020; 11():573823. PubMed ID: 33072116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
    Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.
    Ochi T; Maruta M; Tanimoto K; Kondo F; Yamamoto T; Kurata M; Fujiwara H; Masumoto J; Takenaka K; Yasukawa M
    Commun Biol; 2021 Mar; 4(1):273. PubMed ID: 33654176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.
    Golubovskaya VM; Berahovich R; Xu Q; Zhou H; Xu S; Guan J; Harto H; Li L; Wu L
    Front Biosci (Landmark Ed); 2018 Jun; 23(12):2245-2254. PubMed ID: 29772559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
    Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
    Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
    El Khawanky N; Hughes A; Yu W; Myburgh R; Matschulla T; Taromi S; Aumann K; Clarson J; Vinnakota JM; Shoumariyeh K; Miething C; Lopez AF; Brown MP; Duyster J; Hein L; Manz MG; Hughes TP; White DL; Yong ASM; Zeiser R
    Nat Commun; 2021 Nov; 12(1):6436. PubMed ID: 34750374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30
    Hombach AA; Rappl G; Abken H
    Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
    Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
    Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.